Fjarde Ap Fonden Biomarin Pharmaceutical Inc Transaction History

Fjarde Ap Fonden

$9.04 Billion
Q1 2024

A detailed history of Fjarde Ap Fonden transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Fjarde Ap Fonden holds 63,069 shares of BMRN stock, worth $4.2 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

63,069

Previous 60,769 3.78%

Holding current value

$4.2 Million

Previous $5.86 Million 5.97%

% of portfolio

0.06%

Previous 0.07%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 25, 2024	BUY	$83.81 - $99.0 $192,763 - $227,700	2,300 Added 3.78%	63,069 $5.51 Million
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $868,908 - $1.12 Million	-11,400 Reduced 15.8%	60,769 $5.86 Million
Q3 2023 Oct 23, 2023	BUY	$85.07 - $94.48 $459,377 - $510,192	5,400 Added 8.09%	72,169 $6.39 Million
Q2 2023 Aug 02, 2023	BUY	$86.68 - $100.3 $69,344 - $80,240	800 Added 1.21%	66,769 $5.79 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $157,932 - $211,086	1,800 Added 2.81%	65,969 $6.41 Million
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $1.11 Million - $1.49 Million	-13,700 Reduced 17.59%	64,169 $6.64 Million
Q2 2022 Aug 11, 2022	BUY	$71.48 - $86.85 $893,500 - $1.09 Million	12,500 Added 19.12%	77,869 $6.45 Million
Q1 2022 May 13, 2022	SELL	$74.28 - $92.69 $59,424 - $74,152	-800 Reduced 1.21%	65,369 $5.04 Million
Q4 2021 Feb 15, 2022	SELL	$71.72 - $91.47 $200,816 - $256,116	-2,800 Reduced 4.06%	66,169 $5.85 Million
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $164,494 - $188,034	-2,200 Reduced 3.09%	68,969 $5.33 Million
Q2 2021 Aug 12, 2021	SELL	$75.51 - $84.79 $437,958 - $491,782	-5,800 Reduced 7.54%	71,169 $5.94 Million
Q1 2021 May 17, 2021	BUY	$74.73 - $90.69 $149,460 - $181,380	2,000 Added 2.67%	76,969 $5.81 Million
Q4 2020 Feb 12, 2021	SELL	$72.61 - $90.2 $101,654 - $126,280	-1,400 Reduced 1.83%	74,969 $6.57 Million
Q3 2020 Nov 13, 2020	BUY	$71.87 - $131.03 $395,285 - $720,665	5,500 Added 7.76%	76,369 $5.81 Million
Q2 2020 Aug 13, 2020	BUY	$79.55 - $124.22 $350,020 - $546,568	4,400 Added 6.62%	70,869 $8.74 Million
Q1 2020 May 11, 2020	BUY	$71.37 - $96.85 $435,357 - $590,785	6,100 Added 10.1%	66,469 $5.62 Million
Q4 2019 Feb 10, 2020	BUY	$64.27 - $86.37 $533,441 - $716,871	8,300 Added 15.94%	60,369 $5.1 Million
Q3 2019 Oct 31, 2019	BUY	$67.4 - $85.11 $647,040 - $817,056	9,600 Added 22.6%	52,069 $3.51 Million
Q2 2019 Jul 17, 2019	SELL	$80.35 - $93.9 $1.08 Million - $1.26 Million	-13,400 Reduced 23.98%	42,469 $3.64 Million
Q1 2019 Apr 29, 2019	BUY	$84.2 - $98.62 $825,833 - $967,264	9,808 Added 21.29%	55,869 $4.96 Million
Q4 2018 Jan 31, 2019	SELL	$80.14 - $106.07 $817,428 - $1.08 Million	-10,200 Reduced 18.13%	46,061 $3.92 Million
Q3 2018 Nov 09, 2018	SELL	$93.92 - $105.72 $91,947 - $103,499	-979 Reduced 1.71%	56,261 $5.46 Million
Q2 2018 Jul 12, 2018	BUY	$76.01 - $99.03 $193,825 - $252,526	2,550 Added 4.66%	57,240 $5.39 Million
Q1 2018 May 07, 2018	SELL	$77.67 - $92.63 $147,573 - $175,997	-1,900 Reduced 3.36%	54,690 $4.43 Million
Q4 2017 Feb 12, 2018	BUY	$80.76 - $95.13 $623,467 - $734,403	7,720 Added 15.8%	56,590 $5.05 Million
Q3 2017 Nov 07, 2017	SELL	$80.6 - $94.95 $68,832 - $81,087	-854 Reduced 1.72%	48,870 $4.55 Million
Q2 2017 Aug 08, 2017	BUY	N/A	49,724	49,724 $4.52 Million

Others Institutions Holding BMRN

# of Institutions

627

Shares Held

183M

Call Options Held

1.63M

Put Options Held

1.2M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

News

Stay updated on Fjarde Ap Fonden with notifications on news.

Account